Anavex Nears Alzheimer's Decision With Limited Pipeline Offsets And ATM Overhang [Seeking Alpha]
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: Seeking Alpha
Blarcamesine's EU review has reached Day-180 outstanding issues and an oral explanation, signaling major objections and reduced approval odds. AVXL's schizophrenia candidate, ANAVEX3-71, failed to provide randomized efficacy data, leaving portfolio risk highly concentrated. A $150 million ATM facility and cash near $100 million create significant dilution risk as shares trade near 52-week lows. Jonathan Kitchen/DigitalVision via Getty Images Overview Anavex Life Sciences ( AVXL ) has tumbled 36% since my Strong Sell rating in August. The company is nearing an EU decision on its lead drug candidate, blarcamesine, for the treatment of Alzheimer's disease. Although This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation f
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law FirmBusiness Wire
- Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's [Seeking Alpha]Seeking Alpha
- Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Anavex Life Sciences (NASDAQ:AVXL) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
AVXL
Earnings
- 11/25/25 - Beat
AVXL
Sec Filings
- 11/25/25 - Form 10-K
- 11/25/25 - Form 8-K
- 10/3/25 - Form 4
- AVXL's page on the SEC website